Současné postavení telemedicíny v péči o pacienty s idiopatickými střevními záněty

English version

Autoři: I. Romanko
Působiště autorů: Joint Admission of the General University Hospital for People with Medical Problems, Clinic of Anesthesiology, Resuscitation and Intensive Medicine, 1st Faculty of Medicine and General University Hospital in Prague
Vyšlo v časopise: Gastroent Hepatol 2017; 71(4): 315-322
Kategorie: IBD: přehledová práce
doi: https://doi.org/10.14735/amgh2017315

Souhrn

Specializovaná centra pro léčbu chronických onemocnění, jako jsou idiopatické střevní záněty (IBD – inflammatory bowel disease), jsou často na hranici svých možností při sledování a léčbě pacientů s těmito chorobami. Důvodem je narůstající incidence Crohnovy nemoci a ulcerózní kolitidy a zvyšující se podíl nemocných s těžším průběhem zánětu, kteří vyžadují komplexní péči. V současné době již existují různé způsoby, které umožnují zjednodušení a urychlení komunikace pacienta s příslušným IBD centrem. Využívají se k tomu moderní informační technologie, jako např. webové rozhraní, virtuální kliniky, video komunikace, chytré telefony nebo e-mail. Uplatněním těchto a dalších technologií v medicíně se zabývá telemedicína. V současnosti se stala tématem mnoha diskuzí a výzkumů a stoupá úroveň důkazů o její vhodnosti, propěšnosti a cenové výhodnosti pro lékaře, pacienty i systém zdravotní péče. Tento článek poukazuje na aktuální studie a přehledy pojednávající o současné a budoucí roli telemedicíny, neboli „eHealth“, v péči o IBD pacienty a nabízí pohled na to, jak by využití těchto technologií mělo/mohlo vypadat tak, aby se stali důležitou součástí denní klinické praxe.

Klíčová slova:
idiopatické střevní záněty – Crohnova nemoc – ulcerózní kolitida – telemedicína – eHealth

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Doručeno:
17. 5. 2017

Přijato:
31. 7. 2017

Zdroje

1. Vora P, Shih DQ, McGovern DP et al. Current concepts on the immunopathogenesis of inflammatory bowel disease. Front Biosci (Elite Ed) 2012; 4: 1451–1477.

2. Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: Systematic review and meta-analysis. World J Gastroenterol 2014; 20 (3): 829–842. doi: 10.3748/wjg.v20.i3.829.

3. Berman M1, Fenaughty A. Technology and managed care: patient benefits of telemedicine in a rural health care network. Health Econ 2005; 14 (6): 559–573.

4. Krier M, Kaltenbach T, McQuaid K et al. Potential use of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol 2011; 106 (12): 2063–2067. doi: 10.1038/ajg.2011. 329.

5. Capalbo SM, Heggem CN. Valuing rural health care: issues of access and quality. Am J Agri Econ 1999; 81: 674–670.

6. Barlow C, Cooke D, Mulligan K et al. A critical review of self-management and educational interventions in inflammatory bowel disease. Gastroenterol Nurs 2010; 33 (1): 11–18. doi: 10.1097/SGA.0b013e 3181ca03cc.

7. Siegel CA. Transforming gastroenterology care with telemedicine. Gastroenterology 2017; 152 (2): 958–963. doi: 10.1053/j.gastro.2017.01.048.

8. Romanko I, Lukáš M, Bortlík M. New approaches in follow-up of patients suffering from inflammatory bowel diseases. Gastroent Hepatol 2015; 69 (5): 441–448. doi: 10.14735/amgh2015441.

9. Surti B, Spiegel B, Ippoliti A et al. Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale. Dig Dis Sci 2013; 58 (5): 1313–1321. doi: 10.1007/s10620-012-2500-1.

10. Bodger K, Ormerod C, Shackcloth D et al. Development and validation of a rapid, generic measure of disease control from patient’s perspective: the IBD-control questionnaire. Gut 2014; 63 (7): 1092–1102. doi: 10.1136/gutjnl-2013-305600.

11. Keefer L, Kiebles JL, Taft TH et al. The role of self-efficacy in inflammatory bowel disease management: preliminary validation of a disease-specific measure. Inflamm Bowel Dis 2011; 17 (2): 614–620. doi: 10.1002/ibd.21314.

12. Alrubaiy L, Rikaby I, Dodds P et al. Systematic review of health-related quality of life measures for imflammatory bowel diseases. J Crohn Colitis 2015; 9 (3): 284–292. doi: 10.1093/ecco-jcc/jjv002.

13. Elkjaer M. E-health: Web-guided ther-apy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Dan Med J 2012; 59 (7): B4478.

14. Kim ES, Park KS, Cho KB et al. Development of a web-based, self-reporting symptom diary for Crohn’s disease, and its correlation with the Crohn’s Disease Activity Index: web-based, self-reporting symptom diary for Crohn’s disease. J Crohns Colitis 2014; pii: S1873-9946[14]00268-2. doi: 10.1016/j.crohns.2014.09.003.

15. Jackson BD, Gray K, Knowles SR et al. EHealth Technologies in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2016; 10 (9): 1103–1121. doi: 10.1093/ecco-jcc/jjw059.

16. Pedersen N, Thielsen P, Martinsen L et al. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative collitis. Inflamm Bowel Dis 2014; 20 (12): 2276–2285. doi: 10.1097/MIB.0000000000000199.

17. Pedersen N, Elkjaer M, Duricova D et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther 2012; 36 (9): 840–849.

18. Mc Combie A, Gearry R, Andrews J et al. Does Computerized Cognitive Behavioral Therapy Help People with Inflammatory Bowel Disease? A Randomized Controlled Trial. Inflamm Bowel Dis 2016; 22 (1): 171–181. doi: 10.1097/MIB. 0000000000000567.

19. Calafat M, Cabré E, Mañosa M et al. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis 2015; 21 (5): 1072–1076. doi: 10.1097/MIB.0000000 000000349.

20. Webster K, Odom L, Peterman A et al. The Functional Assessment of Chronic Ill-ness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Qual Life Res 1999; 8: 604.

21. Johnson M, Lithgo K, Price T. IBD-SSHAMP (Supported, Self help and Management Programme); UK’s first Internet based Remote Management System for Managing Stable IBD. Gut 2013; 62: A34–A35. Abstract OC-080.

22. Hunter J, Claridge A, James S et al. Improving outpatient services: the Southampton IBD virtual clinic. Postgrad Med J 2012; 88 (1042): 487–491. doi: 10.1136/ postgradmedj-2012-100123rep.

23. Lichtenstein GR, Rubin D. Gastroenterology Virtual clinic. [online]. Available from: http: //ibdvirtualclinic.com/.

24. ISD Scotland. SMR Datasets, Virtual clinic. [online]. Available from: www.ndc.scot.nhs.uk.

25. Hommel KA, Hente E, Herzer M et al. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol 2013; 25 (4): 469–473. doi: 10.1097/MEG.0b013e 32835c2a1b.

26. Krier M, Kaltenbach T, McQuaid K et al. Potential use of telemedicine to provide outpatient care for inflammatorz bowel disease. Am J Gastroenterol 2011; 106 (12): 2063–2067. doi: 10.1038/ajg.2011.329.

27. Con D, De Cruz P. Mobile phone apps for inflammatory bowel disease self-management: A systematic assessment of content and tools. JMIR Mhealth Uhealth 2016; 4 (1): e13. doi: 10.2196/mhealth.4874.

28. Cross RK, JAmbaulikar G, Langenberg P et al. Telemedicine for patients with inflammatory bowel disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials 2015; 42: 132–144. doi: 10.1016/j.cct.2015.03.006.

29. Atreja A, Khan S, Rogers JD et al. Impact of th Mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: study protocol of pragmatic randomized controlled trial. JMIR Res Protoc 2015; 4 (1): e23. doi: 10.2196/resprot.4042.

30. Plener I, Hayward A, Saibil F. E-mail communication in the management of gastroenterology patients: a review. Can J Gastroenterol Hepatol 2014; 28 (3): 161–165.

31. Aguas Peris M, Del Hoyo J, Bebia P et al. Telemedicine in inflammatory bowel disease: opportunities and approaches. Inflamm Bowel Dis 2015; 21 (2): 392–399. doi: 10.1097/MIB.0000000000000241.

32. Van Deen WK, van der Meulen-de Jong AE, Parekh NK et al. Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health Technologies. Clin Gastroenterol Hepatol 2015; 14 (12): 1742–1750. doi: 10.1016/j.cgh.2015.10.035.

33. Marín-Jiménez I, Nos P, Domènech E et al. Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. Am J Gastroenterol 2016; 111 (2): 261–268. doi: 10.1038/ajg.2015.403.

34. Heida A, Dijkstra A, Groen H et al. Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials 2015; 16: 271. doi: 10.1186/s13063-015-0787-x.

35. Annese V, Daperno M, Rutter MD et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7 (12): 982–1018. doi: 10.1016/j.crohns.2013.09.016.

36. de Jong M, van der Meulen-de Jong A, Romberg-Camps M et al. Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD: MyIBDcoach. Inflamm Bowel Dis 2017; 23 (4): 485–493. doi: 10.1097/MIB.0000000000001034.

37. Vinding KK, Elsberg H, Thorkilgaard T et al. Fecal calprotectin measured by patiens at home using smartphones – a new clinical tool in monitoring patiens with inflammatory bowel disease. Inflamm Bowel Dis 2016; 22 (2): 336–344. doi: 10.1097/MIB.0000000000000619.

38. Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110 (9): 1324–1338. doi: 10.1038/ajg.2015.233.